Company: PETVW
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001493152-25-011967
Chunk: 51

Company: PetVivo Holdings, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 2
Chunk 51
---
.

25

We
believe Spryng® is an optimal solution to safely improve joint function in animals for several reasons:

    ●
    Spryng®
    addresses the underlying problems which relate to deterioration of cartilage causing bones to contact each other and a lack of synovial
    fluid. Spryng® provides a biocompatible lubricious cushion to the joint, which establishes a barrier between the bones,
    thereby protecting the remaining cartilage and bone.

    ●
    Spryng®
    is easily administered with the standard intra-articular injection technique. Multiple joints can be treated simultaneously.

    ●
    Case
    studies indicate many dogs and horses have long-lasting multi-month improvement in lameness after having been treated with Spryng®.

    ●
    After
    receiving a Spryng® injection, many canines are able to discontinue the use of NSAID’s, eliminating the risk
    of negative side effects.

    ●
    Spryng®
    is an effective and economical solution for treating osteoarthritis. A single injection of Spryng® is approximately
    $600 to $900 per joint and typically lasts for at least 12 months.

Historically,
drug sales represent up to 30% of revenues at a typical veterinary practice (Veterinary Practice News). Revenues and margins at veterinary
practices are being eroded because online, big-box, and traditional pharmacies have recently started filling veterinary prescriptions.
Veterinary practices are looking for ways to replace lost prescription revenues with safe and effective products. Spryng®
is a veterinarian-administered medical device that should expand practice revenues and margins. We believe that the increased revenues
and margins provided by Spryng® will accelerate its adoption rate and propel it forward as the standard of care for canine
and equine lameness related to or due to synovial joint issues.

We
commenced sales of Spryng® in the second quarter of fiscal 2022 and plan to increase our commercialization efforts of
Spryng® in the United States through our distribution relationship with MWI Veterinary Supply Co. (“Distributor”
or “MWI”) and the use of sales reps, clinical studies, and market awareness to educate and inform key opinion leaders on
the benefits of Spryng®.

We
entered into a Distribution Services Agreement (“Distribution Agreement”) with MWI on June 17, 2022. Pursuant to the Agreement,
we appointed MWI